stocks logo

AUTL

Autolus Therapeutics PLC
$
2.565
+0.045(1.786%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.585
Open
2.550
VWAP
--
Vol
1.01M
Mkt Cap
670.68M
Low
2.530
Amount
--
EV/EBITDA(TTM)
--
Total Shares
266.04M
EV
407.54M
EV/OCF(TTM)
--
P/S(TTM)
74.42
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.98M
-80.39%
-0.223
+147.57%
--
--
-0.233
-24.81%
--
--
-0.235
+6.76%
Estimates Revision
The market is revising Upward the revenue expectations for Autolus Therapeutics plc (AUTL) for FY2025, with the revenue forecasts being adjusted by 60.26% over the past three months. During the same period, the stock price has changed by 84.53%.
Revenue Estimates for FY2025
Revise Upward
up Image
+60.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.71%
In Past 3 Month
Stock Price
Go Up
up Image
+84.53%
In Past 3 Month
3 Analyst Rating
up Image
289.86% Upside
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
289.86% Upside
Current: 2.565
sliders
Low
10.00
Averages
10.00
High
10.00
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-01-13
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-09
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2024-12-05
Reason

Valuation Metrics

The current forward P/E ratio for Autolus Therapeutics PLC (AUTL.O) is -2.72, compared to its 5-year average forward P/E of -3.26. For a more detailed relative valuation and DCF analysis to assess Autolus Therapeutics PLC 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.26
Current PE
-2.72
Overvalued PE
-1.57
Undervalued PE
-4.96

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.24
Current EV/EBITDA
-2.11
Overvalued EV/EBITDA
-0.53
Undervalued EV/EBITDA
-3.96

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
172.10
Current PS
10.14
Overvalued PS
364.17
Undervalued PS
-19.97

Financials

Annual
Quarterly
FY2025Q1
YoY :
-10.99%
8.98M
Total Revenue
FY2025Q1
YoY :
+68.32%
-65.24M
Operating Profit
FY2025Q1
YoY :
+33.16%
-70.16M
Net Income after Tax
FY2025Q1
YoY :
+8.33%
-0.26
EPS - Diluted
FY2025Q1
YoY :
+104.18%
-83.81M
Free Cash Flow
FY2025Q1
YoY :
-199.86%
-99.86
Gross Profit Margin - %
FY2025Q1
YoY :
+118.14%
-3.15K
FCF Margin - %
FY2025Q1
YoY :
+49.60%
-781.13
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
4.1M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
3.6M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

AUTL News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
07:02:58
Autolus announces EC granted marketing authorization for AUCATZYL
select
2025-05-23 (ET)
2025-05-23
08:31:36
Autolus Therapeutics announces positive CHMP opinion for obe-cel
select
2025-05-14 (ET)
2025-05-14
09:38:17
Autolus Therapeutics presents clinical data updates at EHA Congress
select
Sign Up For More Events

News

9.0
07-21Newsfilter
Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
9.0
06-30Benzinga
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
9.0
06-24PRnewswire
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Sign Up For More News

FAQ

arrow icon

What is Autolus Therapeutics PLC (AUTL) stock price today?

The current price of AUTL is 2.565 USD — it has increased 1.79 % in the last trading day.

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s business?

arrow icon

What is the price predicton of AUTL Stock?

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s revenue for the last quarter?

arrow icon

What is Autolus Therapeutics PLC (AUTL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Autolus Therapeutics PLC (AUTL)'s fundamentals?

arrow icon

How many employees does Autolus Therapeutics PLC (AUTL). have?

arrow icon

What is Autolus Therapeutics PLC (AUTL) market cap?